Extended ( ≥q12 Weeks) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular AMD: Post Hoc Analysis of VIEW Trials

To evaluate outcomes and disease characteristics in eyes with neovascular age-related macular degeneration that received intravitreal aflibercept injection (IAI) and ranibizumab ≥q12 or

Source: American Journal of Ophthalmology - January 18, 2019 Category: Opthalmology Authors: Rahul N. Khurana, Ehsan Rahimy, W. Anthony Joseph, Namrata Saroj, Andrea Gibson, Robert Vitti, Alyson J. Berliner, Karen Chu, YenChieh Cheng, David S. Boyer Tags: Original Articles Source Type: research